Abstract: A fuel tank isolation valve is provided having a main valve body including a fuel tank port and a canister port, a main bore, and an actuator selectively operable to allow or inhibit vented fuel vapors to move from the first port to the second port along a first path. The body can define an airflow bypass orifice that allows vapors to move from the first port, through the main bore, to the second port along a second path, while the actuator is in the closed mode inhibiting vapors from moving along the first path. This flow through the orifice can equalize pressure in a fuel tank and the canister during a purging operation on the canister. The valve can include a fitting that directly couples the valve to the canister without any intermediate hoses, in a cantilevered manner. A related method of use is provided.

Abstract: A fuel tank isolation valve is provided having a main valve body including a fuel tank port and a canister port, a main bore, and an actuator selectively operable to allow or inhibit vented fuel vapors to move from the first port to the second port along a first path. The body can define an airflow bypass orifice that allows vapors to move from the first port, through the main bore, to the second port along a second path, while the actuator is in the closed mode inhibiting vapors from moving along the first path. This flow through the orifice can equalize pressure in a fuel tank and the canister during a purging operation on the canister. The valve can include a fitting that directly couples the valve to the canister without any intermediate hoses, in a cantilevered manner. A related method of use is provided.

Abstract: The invention is based on the discovery of a new bacterial compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Studying the mechanisms implicated in analgesic properties of the probiotic Escherichia coli strain Nissle 1917 (EcN), inventors characterized, the amino fatty acids produced by EcN, which display the Ecn analgesic properties. One of these compounds inhibits the hypersensitivity to colorectal distension induced by capsaicin, which is a very powerful nociceptive compound and acts via the GABA B receptor. Furthermore, inventors demonstrate that this compound is able to cross the cellular epithelial barrier (such as the intestinal epithelium). Thus, the invention relates to a lipopetide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.

Abstract: Provided are polymer compositions made by a process comprising: (a) providing a first reactive composition containing: (i) a polymerization initiator that is capable, upon a first activation, of forming two or more free radical groups, at least one of which is further activatable by subsequent activation; (ii) one or more ethylenically unsaturated compounds; and (iii) a crosslinker; (b) subjecting the first reactive composition to a first activation step such that the first reactive composition polymerizes therein to form a crosslinked substrate network containing a covalently bound activatable free radical initiator, (c) combining the crosslinked substrate network with a second reactive composition containing one or more ethylenically unsaturated compounds; and (d) activating the covalently bound activatable free radical initiator of the crosslinked substrate network such that the second reactive composition polymerizes therein with the crosslinked substrate network to form a grafted polymeric network and a

Abstract: A method of determining the transmittance of a contact lens (200) includes the steps of obtaining a measurement of a first intensity of electromagnetic radiation reflected by ocular surface (100) with an intensity measuring device (400), positioning the contact lens (200) in direct contact with the ocular surface (100), obtaining a measurement of a second intensity of electromagnetic radiation transmitted through the contact lens (200) that is reflected a region (110) of the ocular surface (100) that is covered by the contact lens (200) with the intensity measuring device (400); and calculating the transmittance using the measurements of the first intensity and the second intensity.

Abstract: Provided are ophthalmic devices comprised of a reaction product of a composition comprising: (i) a crosslinked substrate network containing covalently bound activatable free radical initiators; and (ii) a grafting composition containing one or more ethylenically unsaturated compounds. Also provided are processes for making ophthalmic devices.

Abstract: Provided are ophthalmic devices comprised of a reaction product of a composition comprising: (i) a crosslinked substrate network containing covalently bound activatable free radical initiators; and (ii) a grafting composition containing one or more ethylenically unsaturated compounds. Also provided are processes for making ophthalmic devices.

Abstract: Provided are polymer compositions made by a process comprising: (a) providing a first reactive composition containing: (i) a polymerization initiator that is capable, upon a first activation, of forming two or more free radical groups, at least one of which is further activatable by subsequent activation; (ii) one or more ethylenically unsaturated compounds; and (iii) a crosslinker; (b) subjecting the first reactive composition to a first activation step such that the first reactive composition polymerizes therein to form a crosslinked substrate network containing a covalently bound activatable free radical initiator, (c) combining the crosslinked substrate network with a second reactive composition containing one or more ethylenically unsaturated compounds; and (d) activating the covalently bound activatable free radical initiator of the crosslinked substrate network such that the second reactive composition polymerizes therein with the crosslinked substrate network to form a grafted polymeric network and a

Abstract: The present invention relates to the field of immunogenic compositions and vaccines, their manufacture, host cells which can be used in their manufacture and the use of such immunogenic compositions and vaccines in medicine. More particularly, it relates to Klebsiella pneumoniae O-antigens, conjugates comprising a K. pneumoniae O-antigen, host cells suitable for their production and immunogenic compositions or vaccines containing at least one Klebsiella pneumoniae O-antigen.

Abstract: Described are polymerizable high energy light absorbing compounds. The compounds absorb various wavelengths of ultraviolet and/or high energy visible light and are suitable for incorporation in various products, such as biomedical devices and ophthalmic devices. Such devices exhibit a number of desirable properties, including favorable vision break-up times.

Abstract: Described are polymerizable high energy light absorbing compounds. The compounds absorb various wavelengths of ultraviolet and/or high energy visible light and are suitable for incorporation in various products, such as biomedical devices and ophthalmic devices. Such devices exhibit a number of desirable properties, including providing wearers with favorable optical quality.

Abstract: Described are polymerizable high energy light absorbing compounds. The compounds absorb various wavelengths of ultraviolet and/or high energy visible light and are suitable for incorporation in various products, such as biomedical devices and ophthalmic devices. Such devices exhibit a number of desirable properties, including favorable rates of pervaporation.

Abstract: The invention is based on the discovery of a new bacterial compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Studying the mechanisms implicated in analgesic properties of the probiotic Escherichia coli strain Nissle 1917 (EcN), inventors characterized, the amino fatty acids produced by EcN, which display the Ecn analgesic properties. One of these compounds inhibits the hypersensitivity to colorectal distension induced by capsaicin, which is a very powerful nociceptive compound and acts via the GABA B receptor. Furthermore, inventors demonstrate that this compound is able to cross the cellular epithelial barrier (such as the intestinal epithelium). Thus, the invention relates to a lipopeptide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.

Abstract: The invention relates to the field of modified Escherichia coli strain Nissle 1917 (EcN) and its use for treating gastro-in-testinal disorders. The invention is based on the study of the mechanisms implicated in the probiotic properties of the Escherichia coli strain Nissle 1917 (EcN). This study has allowed the inventors to decouple the probiotic activity of EcN from its genotoxic activity by demonstrating that EcN ClbP protein, the enzyme that activates the genotoxin colibactin, is also required for the siderophore-microcins activity of probiotic EcN, but interestingly, not its enzymatic domain that cleaves precolibactin to form active colibactin.

Abstract: A method of determining the transmittance of a contact lens (200) includes the steps of obtaining a measurement of a first intensity of electromagnetic radiation reflected by ocular surface (100) with an intensity measuring device (400), positioning the contact lens (200) in direct contact with the ocular surface (100), obtaining a measurement of a second intensity of electromagnetic radiation transmitted through the contact lens (200) that is reflected a region (110) of the ocular surface (100) that is covered by the contact lens (200) with the intensity measuring device (400); and calculating the transmittance using the measurements of the first intensity and the second intensity.

Abstract: Provided is a contact lens system that comprises: a contact lens containing a photosensitive chromophore and a package surrounding the contact lens. The photosensitive chromophore has at least one active wavelength between 250 and 400 nanometers and at least one active wavelength between 400 and 450 nanometers. The package has a transmittance of no more than 99 percent at each active wavelength.

Abstract: Described are polymerizable high energy light absorbing compounds of formula I: Wherein Y, Pg, R2, R3, R4, R5, and R6 are as described herein. The compounds absorb various wavelengths of ultraviolet and/or high energy visible light and are suitable for incorporation in various products, such as biomedical devices and ophthalmic devices.

Abstract: Provided are polymer compositions made by a process comprising: (a) providing a first reactive composition containing: (i) a polymerization initiator that is capable, upon a first activation, of forming two or more free radical groups, at least one of which is further activatable by subsequent activation; (ii) one or more ethylenically unsaturated compounds; and (iii) a crosslinker; (b) subjecting the first reactive composition to a first activation step such that the first reactive composition polymerizes therein to form a crosslinked substrate network containing a covalently bound activatable free radical initiator, (c) combining the crosslinked substrate network with a second reactive composition containing one or more ethylenically unsaturated compounds; and (d) activating the covalently bound activatable free radical initiator of the crosslinked substrate network such that the second reactive composition polymerizes therein with the crosslinked substrate network to form a grafted polymeric network and a

Abstract: Described are polymerizable high energy light absorbing compounds of formula I: Wherein Y, Pg, R1, R2, R3, R4, R5, and R6 are as described herein. The compounds absorb various wavelengths of ultraviolet and/or high energy visible light and are suitable for incorporation in various products, such as biomedical devices and ophthalmic devices.

Abstract: Provided is a contact lens system that comprises: a contact lens containing a photosensitive chromophore and a package surrounding the contact lens. The photosensitive chromophore has at least one active wavelength between 250 and 400 nanometers and at least one active wavelength between 400 and 450 nanometers. The package has a transmittance of no more than 99 percent at each active wavelength.